The Annual Report Card for the Ontario Drug Benefit Program for their 2015/16 fiscal year has been released. The Report Card provides an overview of the year including financial indicators, cost trends, formulary process & listing times and highlights the Program’s milestones and achievements.
We have included some of the key highlights below:
- Total health expenditures in Ontario in 2015 were $55B
- Drugs accounted for 8.8% of the provincial health expenditures
- Government drug program spending (including drug cost, markup and dispensing fees) increased by 11% since 2014/15 to $5.2B; of that, $4.4B on drug cost alone
- The “top claimants” accounted for almost 50% of the total ODB drug cost
- There has been a 3.9% increase in the number of ODB claims processed in 15/16 compared to 14/15
- Beneficiaries increased by 2% from 2.94M in 14/15 to 3.0M in 15/16
- There was only a slight increase in utilizing beneficiaries since last year
- The top 2 therapeutic classes by number of users are cardiovascular drugs and CNS agents
- The top 2 therapeutic classes by drug cost are unclassified agents (examples: RA, Pompe disease, MS, Crohn’s, multiple myeloma) and CNS agents
- Anti-infective agents were the fastest growing class with an increase in spending of 120% compared to 14/15 driven primarily by drugs for treatment of hepatitis C
- The second fastest growing class was anti-neoplastic agents (oncology) which grew by 19%
- A similar number of new brand products were listed in 15/16 (compared to 14/15):
- Thirty new brand drugs (compared to 34 in 14/15)
- Sixteen new oncology drugs or indications (compared to 13 in 14/15)
- Nine drugs/indications with access increased (identical to 14/15)
For more details, please refer to the complete report which can be accessed through ODB’s website.
To receive updates similar to this one please be sure to sign up for Market Access Signals, our free e-mail newsletter service.